• Home
  • Resources
  • News
  • Pion Inc Unveils New Model of its Industry-First Subcutaneous Injection Site Simulator Investigate Drug Release Performance of Subcutaneous Formulations In Vitro, With New SCISSOR N3

Pion Inc Unveils New Model of its Industry-First Subcutaneous Injection Site Simulator Investigate Drug Release Performance of Subcutaneous Formulations In Vitro, With New SCISSOR N3 

MA. November 16, 2021: Pion Inc, leading provider of analytical instruments that bridge the gap between in vitro experiments and in vivo outcomes launches the SCISSOR N3, its new Subcutaneous Injection Site Simulator. 

Pion was the first company to launch an instrument that enables subcutaneous drug formulators to understand the potential performance of a formulation and dose administration before clinical trials.  Enhanced following customer feedback, the new N3 assesses the risk and performance of subcutaneously administered drugs including biologics, peptides and small molecules by simulating physiological conditions.

Uniquely, SCISSOR N3 is designed to replicate the stress conditions and environmental transitions that a biopharmaceutical, peptide or small molecule drug experiences when injected into a subcutaneous environment. Its sophisticated model features an artificial extracellular matrix which when combined with simulated interstitial fluid in the system, creates a perfect platform to rank order biopharmaceuticals in a bio-relevant human setting, helping to predict in vivo performance. 

Experiments are easy to execute thanks to SCISSOR’s uncomplicated design. Results can be easily manipulated and interpreted to enable meaningful data comparison. In addition, the N3 can run up to three independent assays on a single scissor, simultaneously. It also features an integrated camera as well as  turbidity sensors with increased sensitivity for more effective detection of the physical stability of the drug upon injection. 

“The SCISSOR N3 is the only commercially available solution that bridges the gap between standard dissolution and solubility research, and in vivo Pharmacokinetics (PK) studies, for sub-Q formulations” comments Brian Dutko, President and CEO of Pion Inc. “This launch is the latest addition to our industry-leading range of instruments that help companies confidently decide which drug substances and drug products to progress through the development pipeline while reducing their risk and long-term investment.”

For more information about Pion and to keep up to date with the company’s latest news visit its website or LinkedIn page

Ends

Close